On September 22, 2019, International Oncology Company Roadshow, co-hosted by China Pharmaceutical Innovation and Research Development Association (PhIRDA) and National Foundation for Cancer Research (NFCR), was successfully hosted on the 2019 China BioMed Innovation and Investment Conference (2019 CBIIC). 15 selected projects from the United States, the United Kingdom, South Korea, Sweden, Canada and other countries made excellent roadshows and brought the most cutting-edge information on cancer R&D, which attracted many participants from the medical and investment communities.

By a strict half-year screening and evaluation by NFCR, the International Oncology Company Roadshow concentrated 15 innovative projects from different countries focusing on oncology drugs’ R&D, early-stage screening, diagnosis and precise treatment, as well as representatives who made special trips to Suzhou from miles away, looking forward to find business partners and investors through the influential platform of 2019 CBIIC.

The opening remark was delivered by Dr. Ba Sujuan, President & CEO of NFCR, Founder & CEO of Asian Fund for Cancer Research. Dr. Ba noted that, over the past few years, the trade dispute between China and the United States has exerted a significant impact on cross-border investment and cooperation. Both Chinese and American pharmaceutical industries were facing not only difficulties in cross-border dealing, but also a battle against their common enemy - cancer. Dr. Ba believed that, the war on cancer, as the mission of the world, should gather the united force from medical, research and business leaders, to make contribution on the development of anti-cancer, which could also promote cross-border investment.

Dr. Ba Sujuan made opening remark

On the 1^st Half Morning Session, Professor Raju Kucherlapati, Ph.D., Paul C. Cabot Professor of Genetics and Professor of Medicine, Harvard Medical School, Academician, National Academy of Medicine of USA, made an inspiring presentation on ‘Clinical Applications of Cancer Genetics’, detailing how to use precision medicine to make early-stage cancer screening on individuals at risk for cancer, to extend life expectancy and how to apply genetic information on tumors and artificial intelligence for tailoring most effective treatments for every patient.

Raju Kucherlapati made a keynote speech

On the 2^nd Half Afternoon Session, Ms. Catherine Pan, Partner and Corporate Group Head of Dorsey & Whitney LLP New York Office, gave an opening keynote speech on ‘Legal Issues and Opportunities in Cross-Border Biotech Deals’. Ms. Pan made comment on issues including IP valuation and restrictions on foreign investment in biotech transactions under the background of the China-US trade disputes. The hot topic raised interests from on-site audiences who kept asking questions and made discussion with Ms. Pan, bringing lively atmosphere at the conference.

Ms. Pan in Q&A Session

The 1^st Half Session of International Oncology Company Roadshow was chaired by Dr. Michael Wang, Chief Strategy Officer of NFCR.

Dr. Michael Wang, the 1st Half Session Moderator

Leading innovative companies and organizations, including Oncimmune, Qu Biologics, Sirnaomics, Oxford Biotherapeutics, PharmAbcine, SciTech, OTraces and International Cancer Impact Fund, introduced their products respectively from the aspects of advantages, research achievements and pipeline and so on, involving immunological diagnosis technology, immunomodulation regulator, RNA interference technology, antibody drugs, nano anti-cancer preparations and tumor diagnosis etc.

Roadshow Speakers

The First Row：
Dr. Michael Molyneaux, CMO of Sirnaomics（Left）
Dr. Hal Gunn, CEO of Qu Biologics（Middle）
Dr. Adam Hill, CEO of Oncimmune（Right）
The Second Row：
Dr. Mike Zhao, Head of Asia BD of Oxford Biotherapeutics（Left）
Dr. Jin-San Yoo, CEO of PharmAbcine（Right）
The Third Row：
Mr. Keith Lingenfelter, CEO of OTraces（Left）
Dr. Paul Abrams, Partner of International Cancer Impact Fund（Middle）
Mr. Earle Holsapple, President of SciTech Development（Right）

The 2^nd Half Session of International Oncology Company Roadshow was chaired by Mr. Bradley Gillenwater, Senior Director for Global Program Development of NFCR. 

Mr. Bradley Gillenwater, the 2^nd Half Session Moderator

Representatives from OncoHeroes, Yiviva, Rasio Therapeutics, Stromatis Pharma, Immunicum, 20/20 GeneSystems and Yisheng Biopharma also gave detailed introductions on the adolescent anti-cancer drugs, multi-target anti-cancer drugs, anti-cancer derivatives, immunosuppressive agents, cell therapy, early-stage cancer screening, anti-cancer drugs and so on. The audience was highly interested in the roadshow projects. After the meeting, many companies successfully found partners of their choice through 2019 CBIIC One-on-one Partnering system.

Roadshow Speakers

The First Row：
Dr. Cesare Spadoni, COO of OncoHeroes（Left）
Mr. Sijme Zeilemaker, Senior BD Director of Immunicum（Right）
The Second Row：
Dr. David Shao, CEO of Yisheng Biopharma（Left）
Mr. Peikwen Cheng, CEO of Yiviva（Middle）
Dr. Haiyong Han, Co-founder & Board Member of Stromatis Pharma（Right）
The Third Row：
Dr. Jiming Zhou, VP of East Asia BD 20/20 GeneSystems（Left）
Dr. Alex Meltzer, VP of Drug Discovery of Rasio Therapeutics（Right）

As the third time close cooperation between PhIRDA and NFCR, the International Oncology Company Roadshow have successfully built a platform for direct dialogue and exchange among innovative enterprises, R&D and investment communities at home and abroad, so as to promote and support in-depth cooperation on oncology R&D between domestic and foreign medicine and capital circles.

International Oncology Company Roadshow

Communication among Participants